Kazia Therapeutics (KZIA) Accounts Payables (2009 - 2025)

Kazia Therapeutics has reported Accounts Payables for 15 years, with the latest figure at $6.3 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables fell 7.39% year-over-year to $6.3 million; the trailing twelve-month figure through Dec 2025 stood at $6.3 million (down 7.39% YoY), and the FY2025 full-year result was $6.5 million, down 34.75% from the prior year.
• Accounts Payables for Q4 2025 stood at $6.3 million, down from $6.5 million in the prior quarter.
• The five-year high for Accounts Payables was $9.9 million in Q2 2024, with the low at $2.1 million in Q4 2022.
• Historically, Accounts Payables has averaged $5.0 million across 5 years, with a median of $4.3 million in 2023.
• Annual changes were most pronounced in 2022 — Accounts Payables slumped 56.58% — and 2024, when it jumped 243.19%.
• Kazia Therapeutics' Accounts Payables stood at $4.8 million in 2021, then slumped by 56.58% to $2.1 million in 2022, then jumped by 88.38% to $3.9 million in 2023, then soared by 75.51% to $6.8 million in 2024, then decreased by 7.39% to $6.3 million in 2025.
• The last three Accounts Payables figures came in at $6.3 million (Q4 2025), $6.5 million (Q2 2025), and $6.8 million (Q4 2024), per Business Quant data.